Home
Off-the-shelf
Humanized mice (target-specific)
hGLP-1R
Humanized mice (target-specific)

Preclinical humanized GLP-1R mouse model

Preclinical hGLP-1R model for assessment of agents targeting human GLP-1R

Contact Us

Applications of the hGLP-1R mouse model

Broad range of applications in the fields of metabolism, autoimmunity and neuroscience:

  • Assess the efficacy of GLP-1R targeting compounds, such as in the context of treating type 2 diabetes and obesity
  • Investigate the mode of action (MoA) of various compounds and understand their therapeutic potential

‍

Features

  • Physiological regulation and expression of the humanized GLP-1R
  • Fully functional hGLP-1R
  • Lack of expression of the murine target gene
  • Model is available in a C57BL/6N background
  • Fully functional mouse immune system

Clients

Pfizer

Scientific articleScientific articlePosterPoster

Related resources and publications

osteomyelitis

hyperalgesia

PET imaging

intrauterine growth deficiency

Myopia

ossification

cGAS

cGAS-STING pathway

TFRC

FX-deficiency

muscle-eye-brain disease (MEB)

Tumor microenvironment

primary immunodeficiency (PID)

Oncology

Pharmacology

Neuroscience

Metabolism

Inflammation

Immunology

Respiration

Cardiovascular

Ophthalmology

Nephrology

Musculoskeletal

Hematology

Epigenetics

Development

Endocrinology

Dermatology

Humanization

Rosa26

TET system

Hprt

CreERt2

FLEx

innate immunity

Transgenesis

infection

vision

immune response

dementia

central nervous system (CNS)

taste

transplantation

autoimmunity

thermoregulation

sugar homeostasis

stress

skelet

pulmonary research

pain research

nutrition

muscle research

locomotion

memory

hearing

fat homeostatsis

tissue research

epigentic modification

drugs

cancer research

cell research

behavior

aging

stem cell research

reproductive research

lymphatic system

learning

heart research

gut research

genetic research

exercise

bone research

embryonic development

dental research

blood research

von Willebrand disease (VWD)

X-linked adrenoleukodystrophy (X-ADL)

Vanishing White Matter (VWM) disease

type 2 diabetes (T2D)

ulcerative colitis (UC)

type 1 diabetes (T1D)

thrombosis

thrombocytopenia

systemic lupus erythematosus (SLE)

tauopathy

stenosis

steatohepatitis

spinocerebellar ataxia type 2 (SCA2)

small cell lung cancer

SHORT syndrome

sepsis

schizophrenia

Senescence-associated secretory phenotype (SASP)

seizure

sarcoidosis

rhesus-deficiency syndrome

retinopathy

retinitis pigmentosa (RP)

retinal dystrophy disorder

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
PosterS
(
0
)
Scientific Articles
(
0
)
CommentarIes
(
0
)
Case studies
(
0
)
No results
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial

Nat Med

Jan 2021
No results
The importance of genetic design when choosing your preclinical model - A Case Study on GLP-1R

Physiological relevancy in preclinical models

4 min read
-
Sep 2021
No results

Validation data

Discover related products to

hGLP-1R

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

Preclinical humanized GLP-1R mouse model

Get in touch about

Let us know how we can help

In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.

From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.